Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biocartis and VIB Join Forces

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
Company will develop a new CRC assay for MSI biomarker detection.

Biocartis and VIB have announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC).

This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.

Biocartis’ innovative platform and oncology assays
Biocartis develops the innovative user-friendly diagnostic platform Idylla™, for the molecular analysis of clinical samples.

Biocartis also develops a wide range of clinically relevant tests for various diagnostic areas primarily in the field of oncology. For the development of a new assay for microsatellite instability, Biocartis joins forces with the world-renowned research institute VIB.

Novel MSI biomarkers for colorectal, ovarian and other cancers
Microsatellite instability (MSI) is one of the premier molecular markers in CRC but is also important in ovarian, endometrial and gastric cancers. MSI evolves as a result of inactivation of the DNA mismatch repair (MMR) system and can be found in approximately 15% of all CRCs.

A completely novel set of MSI-markers is now introduced by Prof. Dr. Diether Lambrechts (Vesalius Research Center, VIB, KU Leuven) through whole genome sequencing of colon and endometrial cancers with MMR deficiency.

Prof. Lambrechts commented: “We were able to prove that our novel set of markers has a higher specificity and sensitivity than the current golden standard for MSI. I am very excited about this collaboration with Biocartis, as the clinical application of these markers will facilitate the improved detection of tumors with MSI.”

New colorectal cancer assay for simple and rapid detection
As a result of the license agreement with VIB, Biocartis will develop a new CRC assay for MSI biomarker detection. Today, MSI-testing is vastly underused due to the technical complexity of the current laboratory-developed assays. The availability of a simple and user-friendly assay on Biocartis’ Idylla™ platform has the potential to unlock greatly this considerable market.

Geert Maertens, CSO at Biocartis, commented: “This agreement is a nice example of valorization of new biomarkers from centers of excellence such as the VIB-lab of Prof. Lambrechts. Together with our core panel of colon cancer mutations and the recently in-licensed EGFR S492R mutation from Hospital del Mar, we are building a superior and unique menu for colon cancers assays on our Idylla™ platform.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Invetech and Biocartis Announce Biomarker Collaboration
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.
Wednesday, April 16, 2014
Biocartis and Hospital del Mar Join Forces
License agreement to develop diagnostic colon cancer test.
Monday, October 21, 2013
Scientific News
Oxitec ‘Self-Limiting Gene’ Offers Hope for Controlling Invasive Moth
A new pesticide-free and environmentally-friendly way to control insect pests has moved ahead with the publication of results showing that Oxitec diamondback moths (DBM) with a ‘self-limiting gene’ can dramatically reduce populations of DBM.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
Scientists Identify Schizophrenia’s “Rosetta Stone” Gene
Scientists have identified a critical function of what they believe to be schizophrenia’s “Rosetta Stone” gene that could hold the key to decoding the function of all genes involved in the disease.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
New Research Advances Genetic Studies in Wildlife Conservation
‘Next-gen’ DNA sequencing of non-invasively collected hair expands field of conservation genetics.
AncestryDNA and Calico to Research the Genetics of Human Lifespan
Collaboration will analyze family history and genetics to facilitate development of cutting-edge therapeutics.
Gene Variation Identified for Teen Binge-Eating
Researchers have identified a gene variant which can lead to teenage binge eating, they hope that their work will inform the development of future preventative measures.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
Researchers at the Aortic Institute at Yale have tested the genomes of more than 100 patients with thoracic aortic aneurysms, a potentially lethal condition, and provided genetically personalized care.
Facebook for the Proteome
Researchers have developed a network for describing protein-protein interactions that can then be used to examine protein interactions that may have biological or clinical significance.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!